<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="61070">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02310906</url>
  </required_header>
  <id_info>
    <org_study_id>4053-101</org_study_id>
    <nct_id>NCT02310906</nct_id>
  </id_info>
  <brief_title>Phase I/II Study of SRP-4053 in DMD Patients</brief_title>
  <official_title>A 2-Part, Randomized, Double-Blind, Placebo-Controlled, Dose-Titration, Safety, Tolerability, and Pharmacokinetics Study (Part 1) Followed by an Open-Label Efficacy and Safety Evaluation (Part 2) of SRP-4053 in Patients With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sarepta Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut de Myologie, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Consultants for Research in Imaging and Spectroscopy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Great Ormond Street Hospital for Children NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Holloway University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>SYSNAV</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Newcastle Upon-Tyne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sarepta Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human, multiple-dose 2-part study to assess the safety, tolerability,
      efficacy, and pharmacokinetics of SRP-4053 in Duchenne muscular dystrophy (DMD) patients
      with deletions amenable to exon 53 skipping.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1: Randomized, placebo-controlled dose-titration to assess safety, tolerability and
      pharmacokinetics of 4 dose levels of SRP-4053 in genotypically-confirmed DMD patients with
      deletions amenable to exon 53 skipping.

      Part 2: Open-label evaluation of SRP-4053 in patients from Part 1, along with newly enrolled
      DMD patients with deletions amenable to exon 53 skipping, compared to untreated control DMD
      patients with deletions not amenable to exon 53 skipping.

      Safety, including adverse event monitoring and routine laboratory assessments, will be
      followed on an ongoing basis for all patients.

      Clinical efficacy, including functional tests such as the six-minute walk test (6MWT), will
      be assessed at regularly scheduled study visits. Patients in the treated groups will undergo
      one baseline and one follow-up muscle biopsy. Patients in the untreated control group will
      not undergo biopsies and will follow an abbreviated schedule of study assessments.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>approximately 12 weeks (Part 1)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in 6-Minute Walk Test (6MWT) from Baseline</measure>
    <time_frame>144 weeks (Part 2)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of dystrophin-positive fibers</measure>
    <time_frame>48 weeks (Part 2)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug concentration in plasma</measure>
    <time_frame>Approximately 12 weeks (Part 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum inspiratory pressure (MIP) % predicted, maximum expiratory pressure (MEP) % predicted</measure>
    <time_frame>144 weeks (Part 2)</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>144 weeks (Part 2)</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Duchenne Muscular Dystrophy</condition>
  <arm_group>
    <arm_group_label>Part 1, Part 2 SRP-4053</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 8 genotypically confirmed DMD patients amenable to exon 53 skipping</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Placebo, Part 2 SRP-4053</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Approximately 4 genotypically confirmed DMD patients amenable to exon 53 skipping</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 SRP-4053</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 12 genotypically confirmed DMD patients amenable to exon 53 skipping</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Untreated Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Approximately 24 genotypically confirmed DMD patients with deletions not amenable to exon 53 skipping</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Part 1 Placebo, Part 2 SRP-4053</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SRP-4053</intervention_name>
    <arm_group_label>Part 1, Part 2 SRP-4053</arm_group_label>
    <arm_group_label>Part 1 Placebo, Part 2 SRP-4053</arm_group_label>
    <arm_group_label>Part 2 SRP-4053</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with DMD, genotypically confirmed.

          -  Intact right and left biceps muscles or an alternative upper arm muscle group.

          -  Stable pulmonary and cardiac function.

          -  Minimum performance on 6MWT, North Star Ambulatory Assessment, and rise (Gowers) test
             as specified in the study protocol.

          -  On a stable dose of corticosteroids for at least 6 months.

        Exclusion Criteria:

          -  Previous treatment with the experimental agents BMN-195 (SMT C1100) or PRO053.

          -  Current or previous treatment with any other experimental treatments within 12 weeks
             prior to study entry.

          -  Major surgery within the last 3 months.

          -  Presence of other clinically significant illness.

          -  Major change in physical therapy regime within the last 3 months.

        Other inclusion and exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Genevieve Laforet, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Sarepta Therapeutics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edward Kaye, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Sarepta Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute de Myologie</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario A Gemelli</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle University Hospital</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 25, 2016</lastchanged_date>
  <firstreceived_date>December 3, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Duchenne muscular dystrophy</keyword>
  <keyword>Exon Skipping</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
